[1]郭睿,晋建华.99mTc-depreotide生长抑素受体显像的临床应用研究[J].国际放射医学核医学杂志,2007,31(3):154-157.
 GUO Rui,JIN Jian-hua.The clinical application and study of 99mTc-depreotide somatostatin receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):154-157.
点击复制

99mTc-depreotide生长抑素受体显像的临床应用研究(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
31
期数:
2007年第3期
页码:
154-157
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The clinical application and study of 99mTc-depreotide somatostatin receptor imaging
作者:
郭睿 晋建华
030001 太原, 山西医科大学第一医院核医学科
Author(s):
GUO Rui JIN Jian-hua
Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
受体生长抑素放射性核素显像肺肿瘤乳腺肿瘤甲状腺相关眼病99mTc-depreotide
Keywords:
ReceptorsomatostatinRadinudide imagingThyroid associated ophthalmopathy99mTc-depreotide
分类号:
R817.4
摘要:
生长抑素受体显像近年来研究较多,depreotide已成为其研究热点之一.Depreotide在诊断与鉴别诊断临床常见的孤立性肺结节方面有其独特优势;此外,99mTc-depreotide生长抑素受体显像在乳腺癌、甲状腺癌、淋巴瘤等肿瘤及甲状腺相关性眼病等非肿瘤性疾病也有一定应用前景.
Abstract:
The field of somatostatin receptor imaging (SRI) has made considerable strides in the past few years. Depreotide,a recently developed somatostatin analogue (SSA), has become a hot topic of SRI studies. It plays an important role in the course of diagnosis and differentiation of solitary pulmonary nodules (SPN). Furthermore, it lias much applicative potentials in breast cancer, thyroid carcinoma, lymphoma,thyroid associated ophthalmopathy (TAO), and so on.

参考文献/References:

1 Thomas LP,Balingit AG,Morison DS,et al.False-positive technetium 99m depreotide scintigraphy resulting from round atelectasis.J Thorac Imaging; 2003,18(2):97-99.
2 Blum JE,Handmaker H,Rinne NA,et al.Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer.Curr Pharm Des,2002,8(20):1827-1836.
3 Ferran N,Ricart Y,Lopez M,et al.Characterization of radiologically indeterminate lung lesions:99mTc-depreotide SPECT versus 18F-FDG PET,Nucl Med Commun,2006,27(6):507-514.
4 Gould MK,Maclean CC,Kuschner WG,et al.Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions:a meta-analysis.JAMA,2001,285(7):914-924.
5 Danielsson R,Baath M,Svensson L,et al.Imaging of regional lymph node metastases with 99mTc-depreotide in patients with lung cancer.Eur J Nucl Med Mol Imaging,2005,32(8):925-931.
6 Mena E,Camacho V,Estorch M,et al.99mTc-depreotide scinti-graphy of bone lesions in patients with lung cancer.Eur J Nucl Med Mol Imaging,2004,31(10):1399-1404.
7 Grewal RK,Dadparvar S,Yu JQ,et al.Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonaiy nodules.Cancer J,2002,8(5):400-404.
8 Naalsund A,Maublant J.The solitary pulmonary nodule-is it malignant or benign? Diagnostic performance of 99mTc-depreotide SPECT.Respiration,2006,73(5):634-641.
9 Kahn D,Menda Y,Kemstine K,et al.The utility of 99mTc-depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected nonsmall cell lung cancer.Chest,2004,125 (2):494-501.
10 Van Den Bossche B,Van Belle S,De Winter F,et al.Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy. J Nucl Med,2006,47(1):6-13.
11 Burggasser G,Hurtl I,Hauff W,et al.Orbital scintigraphy with the somatostatin receptor tracer 99mTc-PBIQ in patients with Graves’ disease.J Nucl Med,2003,44(10):1547-1555.
12 Cholewinski W,Kowalczyk JR,Stefaniak B,et al.Diagnosis and staging of children’s lymphoma using the technetium-labelled somatostatin analogue,99mTc-depreotide.Eur J Nucl Med Mol Imaging,2004,31(6):820-824.
13 Vaisamaki P,Gotzamani-Psarrakou A,Tsiouris S,et al.Tc-99m depreotide imaging of I-131-negative recurrent metastatic papillary thyroid carcinoma.Int J Cancer,2006,119(4):968-970.
14 Blankenberg FG,Mari C,Strauss HW.Development of radiocontrast agents for vascular imaging:progress to date.Am J Cardiovasc Drugs,2002,2(6):357-365.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
 Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
 Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
 Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
 Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
 Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
 Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
 ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
 LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
 YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
 BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[11]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
 LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[12]夏伟,吕中伟,王国玉,等.99Tcm标记depreotide及与肺腺癌A549细胞亲和性研究[J].国际放射医学核医学杂志,2010,34(4):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
 XIA Wei,LÜ,Zhong-wei,et al.Experimental studies of depreotide labeled with 99Tcm and the affinity with human lung adenocarcinoma cell line A549[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
[13]高玉婷,王自正.生长抑素类似物介导靶向显像及治疗的研究现状和进展[J].国际放射医学核医学杂志,2009,33(6):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
 GAO Yu-ting,WANG Zi-zheng.The development of somatostatin analogues mediated tumor targeting and therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
[14]侯仁花,吕中伟.生长抑素受体显像剂99mTc-depreotide的研究进展[J].国际放射医学核医学杂志,2008,32(1):15.
 HOU Ren-hua,LÜ,Zhong-wei.The progress of a new somatostatin receptor agent 99mTc-depreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):15.
[15]王秀娟,李险峰.生长抑素受体肿瘤显像的临床应用及研究进展[J].国际放射医学核医学杂志,2006,30(4):217.
 WANG Xiu-juan,LI Xian-feng.Clinical application and progress of somatostatin receptor imaging in diagnosis of cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):217.
[16]王佳琼,王自正,姚薇萱,等.乳腺肿瘤生长抑素受体表达与生长抑素受体显像[J].国际放射医学核医学杂志,2006,30(1):17.
 WANG Jia-qiong,WANG Zi-zheng,YAO Wei-xuan,et al.Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):17.
[17]章斌.188Re直接标记octreotide的方法学[J].国际放射医学核医学杂志,2002,26(5):220.
 ZHANG Bin.Investigations of directly labelling octreotide with 188Re[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(3):220.

备注/Memo

备注/Memo:
收稿日期:2006-11-20。
通讯作者:晋建华,E-mail:jjhl225@126.com
更新日期/Last Update: 1900-01-01